BRD2 and plasma cell myeloma: Selective inhibition has differential effects: BRD4 inhibition alone suppresses tumor growth in multiple myeloma, AML, and solid tumors, whereas dual BRD2/BRD4 inhibition is often required in resistant models (6, 29).